Cancer
GSK skin cancer drugs moves into phase III
January 25, 2011Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer
GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …
Novartis offers $470m to boost personalised cancer treatment
January 24, 2011Research and Development, Sales and Marketing Cancer, Genoptix, Novartis, cancer diagnostics, personalised medicine
Novartis has offered $470 million for a California-based laboratory whose diagnostic services it hopes will enhance personalised treatment. Genoptix specialises …
Trial success for Roche’s personalised skin cancer drug
January 19, 2011Research and Development BRAF V600, Cancer, RG7204, Roche, personalised medicine, skin cancer
A promising Roche drug has helped previously untreated patients with advanced skin cancer to live longer without their disease getting …
Anti-cancer stem cell drug starts clinical trials
January 14, 2011Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers
OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …
Pfizer lung cancer drug gets ‘rolling’ fast-track status in US
January 13, 2011Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer
Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …
New cancer strategy gets £750 million boost
January 13, 2011Cancer, NHS, cancer funding, cancer strategy
The government has published a new ‘Strategy for Cancer’ that seeks to increase preventive measures and improve outcomes for oncology …
Amgen aims for oncology expansion and a wider denosumab license
January 12, 2011Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib
Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …
Dendreon eyes late 2011 European cancer vaccine filing
January 10, 2011Sales and Marketing Cancer, Denreon, Provenge, cancer vaccine, sipuleucel, vaccines
Dendreon Group is to seek marketing authorisation in Europe for the world’s first immunotherapy cancer vaccine in late 2011 or …
Gilead set to acquire Arresto for $225 million
December 23, 2010Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis
Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …
Sanofi signs new oncology research deals
December 20, 2010Research and Development Avila Therapeutics, Cancer, INDOX, India, Oxford University, Sanofi, Sanofi-Aventis, cancer research, covalent drugs
Sanofi-Aventis has signed two new cancer research deals, including one that will see it partner with Avila Therapeutics to discover …
Sanofi and Merck Serono to collaborate in oncology
December 17, 2010Research and Development Cancer, MSC1936369B, Merck Serono, SAR245408, SAR245409, Sanofi, Sanofi-Aventis
Sanofi-Aventis and Merck Serono are to join forces to study three new cancer drug candidates. The collaboration will see the companies …
Tolerx to collaborate on first-in-class cancer antibody
December 2, 2010Research and Development Cancer, T cell, Torelx, monoclonal antibody
US biopharma company Tolerx is to work with a non-profit cancer research fund to develop its first in class antibody …
Pharma unprepared for personalised oncology
November 29, 2010Research and Development, Sales and Marketing Cancer, ESMO, ESMO Cancer Biology for Clinicians Symposium, oncology, personalised medicine
The new era of personalised cancer care requires different thinking from pharma companies, according to experts at the ESMO symposium. …
NICE recommends Herceptin for gastric cancer, blocks high dose Glivec
November 24, 2010Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer
NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
Denosumab approved for bone cancer use
November 19, 2010Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab
Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
